MedTrace Logo

Bone Loss in Men on Androgen Blockade as Adjuvant Therapy for Prostate Cancer

NCT00199537 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 25

Last updated 2008-07-29

No results posted yet for this study

Summary

Patients with advanced prostate cancer undergoing adjuvant treatment with androgen blockade will be followed over a 1 year interval to assess the effects of this treatment on bone metabolism. It is expected that men undergoing androgen blockade will experience accelerated bone loss.

Conditions

Sponsors & Collaborators

  • Lawson Health Research Institute Internal Review Fund

    collaborator UNKNOWN

  • University of Western Ontario, Canada

    collaborator OTHER

  • London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

    lead OTHER

Principal Investigators

  • Hassan Razvi, MD, FRCSC · Urology, St. Joseph's Hospital, University of Western Ontario

Eligibility

Min Age
40 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-02-28
Primary Completion
2008-02-29
Completion
2008-02-29

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00199537 on ClinicalTrials.gov